journal article·2024-08-07

Constructing Heavy-Atom-Free Photosensitizers for Hypoxic Tumor Phototherapy Based on Donor-Excited Photoinduced Electron-Transfer-Driven Type-I and Type-II Mechanisms

Junfeng Miao, Guangxiao Yao, Yingying Huo, Beibei Wang, Wei Zhao, Wei Guo

ACS Applied Materials & Interfaces· Volume 16· Issue 31
Publisher page

Abstract

The spin–orbit charge transfer intersystem crossing (SOCT-ISC) photophysical process has shown great potential for constructing heavy-atom-free photosensitizers (PSs) for photodynamic therapy (PDT) of tumors. However, for almost all such PSs reported to date, the SOCT-ISC is driven by the acceptor-excited photoinduced electron transfer ( a -PeT). In this work, for the first time the donor-excited photoinduced electron transfer ( d -PeT)-driven SOCT-ISC mechanism is utilized to construct the heavy-atom-free PSs for PDT of tumors by directly installing the electron-deficient N -alkylquinolinium unit (as an electron acceptor) into the meso -position of the near-infrared (NIR) distyryl Bodipy chromophore (as an electron donor). In the less polar environment, the PSs exist as the monomer and promote the production of singlet oxygen ( 1 O 2 ) (Type-II) relying on the d -PeT-driven population of the triplet excited state via SOCT-ISC, whereas in the aqueous environment, they exist as nanoaggregates and induce the generation of superoxides (O 2 –• ) and hydroxyl radicals (HO • ) (Type-I) via the d -PeT-driven formation of the delocalized charge-separated state. The PSs could rapidly be internalized into cancer cells and induce the simultaneous production of intracellular 1 O 2, O 2 –•, and HO • upon NIR light irradiation, endowing the PSs with superb photocytotoxicity with IC 50 values up to submicromolar levels whether under normoxia or under hypoxia. Based on the PSs platform, a tumor-targetable PS is developed, and its abilities in killing cancer cells and in ablating tumors without damage to normal cells/tissues under NIR light irradiation are verified in vitro and in vivo . The study expands the design scope of PSs by introducing the d -PeT conception, thus being highly valuable for achieving novel PSs in the realm of tumor PDT.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemistry and Chemical Engineering, Shanxi University, Taiyuan 030006, China

Funding

National Natural Science Foundation of China

References (60)

Show source-provided references
1. 10.1039/B915149B10.1039/B915149B ↗
2. 10.1039/C2CS35216H10.1039/C2CS35216H ↗
3. 10.1039/D0CS00173B10.1039/D0CS00173B ↗
4. 10.1002/anie.20180513810.1002/anie.201805138 ↗
5. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
6. 10.3390/app1219993310.3390/app12199933 ↗
7. 10.1021/acs.accounts.2c0053110.1021/acs.accounts.2c00531 ↗
8. 10.1002/anie.20201029410.1002/anie.202010294 ↗
9. 10.1021/jacs.3c0104210.1021/jacs.3c01042 ↗
10. 10.1038/s41467-022-29862-910.1038/s41467-022-29862-9 ↗
11. 10.1021/jacs.8b0865810.1021/jacs.8b08658 ↗
12. 10.1021/jacs.0c0073410.1021/jacs.0c00734 ↗
13. 10.1021/jacs.1c0737210.1021/jacs.1c07372 ↗
14. 10.1038/s41557-019-0328-410.1038/s41557-019-0328-4 ↗
15. 10.1021/jacs.2c1186810.1021/jacs.2c11868 ↗
16. 10.1038/s41467-022-33924-310.1038/s41467-022-33924-3 ↗
17. 10.1002/anie.20210674810.1002/anie.202106748 ↗
18. 10.1002/anie.20201322810.1002/anie.202013228 ↗
19. 10.1038/nrc107110.1038/nrc1071 ↗
20. 10.1021/acs.accounts.0c0060610.1021/acs.accounts.0c00606 ↗
21. 10.1039/C9OB02170A10.1039/C9OB02170A ↗
22. 10.1021/jp800561g10.1021/jp800561g ↗
23. 10.1021/jacs.7b0055110.1021/jacs.7b00551 ↗
24. 10.1021/acs.jpca.7b0762310.1021/acs.jpca.7b07623 ↗
25. 10.1021/acs.orglett.7b0204710.1021/acs.orglett.7b02047 ↗
26. 10.1002/anie.20200943910.1002/anie.202009439 ↗
27. 10.1039/C9CC09058D10.1039/C9CC09058D ↗
28. 10.1002/chem.20190430610.1002/chem.201904306 ↗
29. 10.1021/jacs.1c0627510.1021/jacs.1c06275 ↗
30. 10.1016/j.jlumin.2017.10.01810.1016/j.jlumin.2017.10.018 ↗
31. 10.1002/asia.20170079410.1002/asia.201700794 ↗
32. 10.1039/C9BM01709G10.1039/C9BM01709G ↗
33. 10.1021/ja048241k10.1021/ja048241k ↗
34. 10.1021/ja906064610.1021/ja9060646 ↗
35. 10.1002/cphc.20070006010.1002/cphc.200700060 ↗
36. 10.1002/anie.20220181510.1002/anie.202201815 ↗
37. 10.1002/adma.20230516310.1002/adma.202305163 ↗
38. 10.1002/anie.20231878310.1002/anie.202318783 ↗
39. 10.1039/D1CC04685C10.1039/D1CC04685C ↗
40. 10.1021/jacs.0c0918510.1021/jacs.0c09185 ↗
41. 10.1021/acs.accounts.0c0039710.1021/acs.accounts.0c00397 ↗
42. 10.1021/acs.jpca.7b0762310.1021/acs.jpca.7b07623 ↗
43. 10.1039/C7AN02041D10.1039/C7AN02041D ↗
44. 10.1016/j.snb.2017.12.08910.1016/j.snb.2017.12.089 ↗
45. 10.1016/j.snb.2017.12.01110.1016/j.snb.2017.12.011 ↗
46. 10.1039/c8pp00113h10.1039/c8pp00113h ↗
47. 10.1039/C6NR03656B10.1039/C6NR03656B ↗
48. 10.1021/jacs.1c0915510.1021/jacs.1c09155 ↗
49. 10.1002/adma.20190785510.1002/adma.201907855 ↗
50. 10.1021/jacs.0c0147310.1021/jacs.0c01473 ↗
51. 10.1016/j.chempr.2018.06.00310.1016/j.chempr.2018.06.003 ↗
52. 10.1021/jacs.9b1180010.1021/jacs.9b11800 ↗
53. 10.1002/advs.20230190210.1002/advs.202301902 ↗
54. 10.1002/ange.20220375810.1002/ange.202203758 ↗
55. 10.1021/jacs.1c0915510.1021/jacs.1c09155 ↗
56. 10.1038/nm.255410.1038/nm.2554 ↗
57. 10.1039/C5CC09248E10.1039/C5CC09248E ↗
58. 10.1002/anie.20160413010.1002/anie.201604130 ↗
59. 10.1039/C7CS00907K10.1039/C7CS00907K ↗
60. 10.1002/anie.20170479310.1002/anie.201704793 ↗